Study drug for hard-to-treat CLL or SLL after relapse
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1/2 study tests APG2575 alone or combined with other treatment in people whose CLL/SLL has come back or did not respond to prior therapy. The goal is to see how well the treatment works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have CLL or SLL that has relapsed or is refractory (not responding to treatment).
- Your overall health is good enough for study treatment (ECOG 0–1).
- Your heart rhythm measurement (QTcF) is within limits for your sex.
- Your kidneys, liver, and bone marrow are functioning well enough for treatment.
- You can and agree to follow birth-control rules during treatment and for 3 months after the last dose (or you are not a pregnancy-capable person).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies APG-2575 in people with CLL/SLL that has come back or is not responding to prior treatments. It may help shrink disease and improve control when standard options have stopped working.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This Phase 1 study tests an oral (by mouth) drug called LP-118 in people whose blood cancers have returned or did not respond to prior treatment. The goal is to find a safe dose and see whether it can shrink or control the cancer.
This trial tests a new drug called APG2575 for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have been taking a BTK inhibitor for at least 12 months. The goal is to see if adding APG2575 can help control the disease better.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.